SCHEMBL2322160

SCHEMBL2322160

Fc1ccc(-n2ncc(-c3cc4c(nn3)C3CCC4C3)c2C(F)(F)F)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.45
SMN1; SMN2 Q16637 4/20 0.44
HTT P42858 2/20 0.44
ALDH1A1 P00352 2/20 0.39
POLB P06746 2/20 0.39
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CYP17A1 P05093 2/20 0.35
CYP1A2 P05177 2/20 0.35
P2RX7 Q99572 1/20 0.34
NR3C1 P04150 6/20 0.33
PGR P06401 2/20 0.33
PDK1 Q15118 1/20 0.31
PDK2 Q15119 1/20 0.31
HSD11B1 P28845 1/20 0.31
CA1 P00915 1/20 0.30
CA2 P00918 1/20 0.30
CA4 P22748 1/20 0.30
CA9 Q16790 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2323395 0.78 KDM4E (0.30)
SCHEMBL2325765 0.75 LMNA (0.44) LMNASMN1; SMN2HTTALDH1A1POLB
SCHEMBL2325391 0.75 AR (0.40)
SCHEMBL2322258 0.75 NOTUM (0.34)
SCHEMBL1382475 0.74 LMNA (0.47) LMNASMN1; SMN2HTTALDH1A1POLB
SCHEMBL1384289 0.74 LMNA (0.47) LMNASMN1; SMN2HTTALDH1A1POLB
SCHEMBL2327315 0.73 GRM4 (0.39) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL2322937 0.71 CYP11B1 (0.37)
SCHEMBL2325632 0.69 TRPA1 (0.43) MEN1KMT2ACYP1A2HSD11B1
SCHEMBL2321845 0.69 CYP11B1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904455-B1 PYRIDAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-17 EP claimed
US-7678795-B2 Pyridazines as 11b-HSD1 inhibitors HOFFMAN-LA ROCHE INC. (US) 2010-03-16 US claimed
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. 2007-01-11 US claimed
EP-1904455-B1 PYRIDAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-17 EP disclosed
US-7678795-B2 Pyridazines as 11b-HSD1 inhibitors HOFFMAN-LA ROCHE INC. (US) 2010-03-16 US disclosed
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HSD11B1, HSD17B1, HSD17B11 LMNA 2625/4885SMN1; SMN2 2843/4885HTT 3917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.